-
Je něco špatně v tomto záznamu ?
The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM
MA. Mohtar, L. Hernychova, JR. O'Neill, ML. Lawrence, E. Murray, B. Vojtesek, TR. Hupp,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2002 do Před 1 rokem
Freely Accessible Science Journals
od 2002
PubMed Central
od 2008
Europe PubMed Central
od 2008 do Před 1 rokem
Open Access Digital Library
od 2002-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
PubMed
29339412
DOI
10.1074/mcp.ra118.000573
Knihovny.cz E-zdroje
- MeSH
- adhezní molekula epiteliálních buněk genetika metabolismus MeSH
- lidé MeSH
- MFC-7 buňky MeSH
- peptidy metabolismus MeSH
- proteiny genetika metabolismus MeSH
- protoonkogenní proteiny c-mdm2 metabolismus MeSH
- rekombinantní proteiny metabolismus MeSH
- vazba proteinů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AGR2 is an oncogenic endoplasmic reticulum (ER)-resident protein disulfide isomerase. AGR2 protein has a relatively unique property for a chaperone in that it can bind sequence-specifically to a specific peptide motif (TTIYY). A synthetic TTIYY-containing peptide column was used to affinity-purify AGR2 from crude lysates highlighting peptide selectivity in complex mixtures. Hydrogen-deuterium exchange mass spectrometry localized the dominant region in AGR2 that interacts with the TTIYY peptide to within a structural loop from amino acids 131-135 (VDPSL). A peptide binding site consensus of Tx[IL][YF][YF] was developed for AGR2 by measuring its activity against a mutant peptide library. Screening the human proteome for proteins harboring this motif revealed an enrichment in transmembrane proteins and we focused on validating EpCAM as a potential AGR2-interacting protein. AGR2 and EpCAM proteins formed a dose-dependent protein-protein interaction in vitro Proximity ligation assays demonstrated that endogenous AGR2 and EpCAM protein associate in cells. Introducing a single alanine mutation in EpCAM at Tyr251 attenuated its binding to AGR2 in vitro and in cells. Hydrogen-deuterium exchange mass spectrometry was used to identify a stable binding site for AGR2 on EpCAM, adjacent to the TLIYY motif and surrounding EpCAM's detergent binding site. These data define a dominant site on AGR2 that mediates its specific peptide-binding function. EpCAM forms a model client protein for AGR2 to study how an ER-resident chaperone can dock specifically to a peptide motif and regulate the trafficking a protein destined for the secretory pathway.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012910
- 003
- CZ-PrNML
- 005
- 20190418083333.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1074/mcp.RA118.000573 $2 doi
- 035 __
- $a (PubMed)29339412
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mohtar, M Aiman $u From the ‡University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom, EH4 2XR. §National University of Malaysia, UKM Medical Molecular Biology Institute (UMBI), 56000 Kuala Lumpur, Malaysia.
- 245 14
- $a The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM / $c MA. Mohtar, L. Hernychova, JR. O'Neill, ML. Lawrence, E. Murray, B. Vojtesek, TR. Hupp,
- 520 9_
- $a AGR2 is an oncogenic endoplasmic reticulum (ER)-resident protein disulfide isomerase. AGR2 protein has a relatively unique property for a chaperone in that it can bind sequence-specifically to a specific peptide motif (TTIYY). A synthetic TTIYY-containing peptide column was used to affinity-purify AGR2 from crude lysates highlighting peptide selectivity in complex mixtures. Hydrogen-deuterium exchange mass spectrometry localized the dominant region in AGR2 that interacts with the TTIYY peptide to within a structural loop from amino acids 131-135 (VDPSL). A peptide binding site consensus of Tx[IL][YF][YF] was developed for AGR2 by measuring its activity against a mutant peptide library. Screening the human proteome for proteins harboring this motif revealed an enrichment in transmembrane proteins and we focused on validating EpCAM as a potential AGR2-interacting protein. AGR2 and EpCAM proteins formed a dose-dependent protein-protein interaction in vitro Proximity ligation assays demonstrated that endogenous AGR2 and EpCAM protein associate in cells. Introducing a single alanine mutation in EpCAM at Tyr251 attenuated its binding to AGR2 in vitro and in cells. Hydrogen-deuterium exchange mass spectrometry was used to identify a stable binding site for AGR2 on EpCAM, adjacent to the TLIYY motif and surrounding EpCAM's detergent binding site. These data define a dominant site on AGR2 that mediates its specific peptide-binding function. EpCAM forms a model client protein for AGR2 to study how an ER-resident chaperone can dock specifically to a peptide motif and regulate the trafficking a protein destined for the secretory pathway.
- 650 _2
- $a adhezní molekula epiteliálních buněk $x genetika $x metabolismus $7 D000071858
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a peptidy $x metabolismus $7 D010455
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a proteiny $x genetika $x metabolismus $7 D011506
- 650 _2
- $a protoonkogenní proteiny c-mdm2 $x metabolismus $7 D051736
- 650 _2
- $a rekombinantní proteiny $x metabolismus $7 D011994
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hernychova, Lenka $u ¶Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
- 700 1_
- $a O'Neill, J Robert $u From the ‡University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom, EH4 2XR.
- 700 1_
- $a Lawrence, Melanie L $u From the ‡University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom, EH4 2XR.
- 700 1_
- $a Murray, Euan $u From the ‡University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom, EH4 2XR. ¶Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
- 700 1_
- $a Vojtesek, Borek $u ¶Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
- 700 1_
- $a Hupp, Ted R $u From the ‡University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom, EH4 2XR; ted.hupp@ed.ac.uk. ¶Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. ‖University of Gdansk, International Centre for Cancer Vaccine Science, ul. Wita Stwosza 63, 80-308 Gdansk, Poland.
- 773 0_
- $w MED00007436 $t Molecular & cellular proteomics MCP $x 1535-9484 $g Roč. 17, č. 4 (2018), s. 737-763
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29339412 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190418083400 $b ABA008
- 999 __
- $a ok $b bmc $g 1392220 $s 1051215
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 17 $c 4 $d 737-763 $e 20180116 $i 1535-9484 $m Molecular and cellular proteomics $n Mol Cell Proteomics $x MED00007436
- LZP __
- $a Pubmed-20190405